Insider Transactions in Q4 2025 at Adaptive Biotechnologies Corp (ADPT)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2025
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
4,394
-1.37%
|
$74,698
$17.5 P/Share
|
|
Dec 22
2025
|
Francis Lo Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,394
+0.46%
|
$26,364
$6.75 P/Share
|
|
Dec 15
2025
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
113,890
-26.49%
|
$1,708,350
$15.57 P/Share
|
|
Dec 15
2025
|
Francis Lo Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
97,022
+7.49%
|
$582,132
$6.75 P/Share
|
|
Dec 10
2025
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
22,968
-32.96%
|
$367,488
$16.0 P/Share
|
|
Dec 04
2025
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
12,604
-4.07%
|
$201,664
$16.85 P/Share
|
|
Dec 04
2025
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
12,604
+1.36%
|
$100,832
$8.2 P/Share
|
|
Dec 04
2025
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-0.81%
|
$160,000
$16.61 P/Share
|
|
Dec 03
2025
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
27,212
-2.14%
|
$489,816
$18.61 P/Share
|
|
Dec 01
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
124,998
-4.41%
|
$2,249,964
$18.94 P/Share
|
|
Nov 28
2025
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
162,820
-42.91%
|
$3,093,580
$19.5 P/Share
|
|
Nov 28
2025
|
Kyle Piskel Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
110,114
+8.43%
|
$880,912
$8.83 P/Share
|
|
Nov 26
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
35,736
-1.25%
|
$678,984
$19.68 P/Share
|
|
Nov 21
2025
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
308,477
-50.97%
|
$4,935,632
$16.91 P/Share
|
|
Nov 21
2025
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
308,477
+9.48%
|
$2,159,339
$7.13 P/Share
|
|
Nov 20
2025
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
297,925
-50.1%
|
$4,766,800
$16.54 P/Share
|
|
Nov 20
2025
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
201,993
+15.29%
|
$2,019,930
$10.3 P/Share
|
|
Nov 17
2025
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
238
-0.09%
|
$3,332
$14.05 P/Share
|
|
Nov 12
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
1,867
-0.07%
|
$28,005
$15.0 P/Share
|
|
Nov 11
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
1,237
-0.04%
|
$17,318
$14.57 P/Share
|
|
Nov 10
2025
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-0.78%
|
$140,000
$14.82 P/Share
|
|
Nov 10
2025
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
86,161
-2.91%
|
$1,206,254
$14.73 P/Share
|